Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2022

29.08.2022 | short review

Molecular profiling in colorectal cancer

verfasst von: Msc Gudrun Piringer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Despite recent advances in the management of colorectal cancer, metastatic disease remains challenging and patients are rarely cured. Chemotherapy with 5‑fluoruracil remains the backbone of therapy in metastatic colorectal cancer. The addition of oxaliplatin and irinotecan as well as the addition of monoclonal antibodies against vascular endothelial growth factor or in RAS wild-type tumors against the epidermal growth factor receptor improves outcome. A better understanding of molecular pathways in cancer cells has led to the development of targeted therapies. Some of these targeted therapies show promising activity in subtypes of metastatic colorectal cancer and have been approved by the European Medicines Agency. This review provides an overview of the role of targeted therapies in the management of patients with metastatic colorectal cancer.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel R, et al. Global Cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. PubMed Sung H, Ferlay J, Siegel R, et al. Global Cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. PubMed
2.
3.
Zurück zum Zitat Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2:459–71. CrossRef Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2:459–71. CrossRef
4.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med. 2004;350:2335–42. CrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med. 2004;350:2335–42. CrossRef
5.
Zurück zum Zitat Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–34506. CrossRef Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–34506. CrossRef
6.
Zurück zum Zitat Saltz L, Clarke S, Dìaz-Rubino E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomised phase III study. J Clin Oncol. 2008;26:2013–9. CrossRef Saltz L, Clarke S, Dìaz-Rubino E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomised phase III study. J Clin Oncol. 2008;26:2013–9. CrossRef
7.
Zurück zum Zitat Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluroouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705. CrossRef Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluroouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705. CrossRef
8.
Zurück zum Zitat Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med. 2009;360:1408–17. CrossRef Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med. 2009;360:1408–17. CrossRef
9.
Zurück zum Zitat Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that proceed during or after first-line therapy with bevacizumab, oxaliplatin and a fluoropyrimidine (RAISE): a randomised, double-blind, multicencer, phase 3 study. Lancet Oncol. 2015;16:499–508. CrossRef Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that proceed during or after first-line therapy with bevacizumab, oxaliplatin and a fluoropyrimidine (RAISE): a randomised, double-blind, multicencer, phase 3 study. Lancet Oncol. 2015;16:499–508. CrossRef
10.
Zurück zum Zitat Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Eng J Med. 2009;361:2449–60. CrossRef Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Eng J Med. 2009;361:2449–60. CrossRef
11.
Zurück zum Zitat Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treamtnet of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15. CrossRef Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treamtnet of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15. CrossRef
12.
Zurück zum Zitat Cremolini A, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab in the tramtne of patients with metastatic colorectal cancer (TRIBE 2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:497–507. CrossRef Cremolini A, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab in the tramtne of patients with metastatic colorectal cancer (TRIBE 2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:497–507. CrossRef
13.
Zurück zum Zitat Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;38:3314–24. CrossRef Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;38:3314–24. CrossRef
14.
Zurück zum Zitat Kopetz S, Grothey A, Yaeger R, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer. N Eng J Med. 2019;381:1632–43. CrossRef Kopetz S, Grothey A, Yaeger R, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer. N Eng J Med. 2019;381:1632–43. CrossRef
15.
Zurück zum Zitat Lapeyre-Prost A, Terme M, Pernot S, et al. Immune therapy in colorectal cancer. Colorectal Cancer. 2017;6:1–10. CrossRef Lapeyre-Prost A, Terme M, Pernot S, et al. Immune therapy in colorectal cancer. Colorectal Cancer. 2017;6:1–10. CrossRef
16.
Zurück zum Zitat André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Eng J Med. 2020;383:2207–18. CrossRef André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Eng J Med. 2020;383:2207–18. CrossRef
17.
Zurück zum Zitat Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J Clin Oncol. 2020;38(4_suppl):11. CrossRef Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J Clin Oncol. 2020;38(4_suppl):11. CrossRef
18.
Zurück zum Zitat Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 Keynote-158 study. Lancet Oncol. 2020;21:1353–65. CrossRef Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 Keynote-158 study. Lancet Oncol. 2020;21:1353–65. CrossRef
19.
Zurück zum Zitat Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term clinical outcome of trastzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19(4):256–262.e2. CrossRef Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term clinical outcome of trastzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19(4):256–262.e2. CrossRef
20.
Zurück zum Zitat Meric-Bernstam F, Hainsworth J, Bose R, et al. MyPathway Her2 basket study. Pertuzumab + trastuzumab treatment of a large, tissue-agnostic cohort of patients with Her2-positive advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):3004. CrossRef Meric-Bernstam F, Hainsworth J, Bose R, et al. MyPathway Her2 basket study. Pertuzumab + trastuzumab treatment of a large, tissue-agnostic cohort of patients with Her2-positive advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):3004. CrossRef
21.
Zurück zum Zitat Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINGY-CRC01): a multicenter, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89. CrossRef Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINGY-CRC01): a multicenter, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89. CrossRef
22.
Zurück zum Zitat Stickler JH, Ng K, Cercek A, et al. MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. J Clin Oncol. 2021;39(3_suppl):TPS153. CrossRef Stickler JH, Ng K, Cercek A, et al. MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. J Clin Oncol. 2021;39(3_suppl):TPS153. CrossRef
23.
Zurück zum Zitat Hong D, Fakih MG, Strickler JH, et al. KRAS G12C Inhibition with Sotorasib in advanced solid tumors. N Eng J Med. 2020;383:1207–17. CrossRef Hong D, Fakih MG, Strickler JH, et al. KRAS G12C Inhibition with Sotorasib in advanced solid tumors. N Eng J Med. 2020;383:1207–17. CrossRef
24.
Zurück zum Zitat Fakih M, Falchook G, Hong D, et al. CodeBreaK 101 subprotocol H: phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC). Ann Oncol. 2021;32:S530–S82. CrossRef Fakih M, Falchook G, Hong D, et al. CodeBreaK 101 subprotocol H: phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC). Ann Oncol. 2021;32:S530–S82. CrossRef
25.
Zurück zum Zitat Weiss J, Yaeger R, Johnson M, et al. KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2021;32:S1283–S96. Weiss J, Yaeger R, Johnson M, et al. KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2021;32:S1283–S96.
26.
Zurück zum Zitat Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positiv cancers in adults and children. N Engl J Med. 2018;378:731–9. CrossRef Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positiv cancers in adults and children. N Engl J Med. 2018;378:731–9. CrossRef
27.
Zurück zum Zitat Hsiao SY, He HL, Weng TS, et al. Colorectal cancer with EML4-ALK fusion gene response to aletinib: a case report and review of the literature. Case Rep Oncol. 2021;14:232–8. CrossRef Hsiao SY, He HL, Weng TS, et al. Colorectal cancer with EML4-ALK fusion gene response to aletinib: a case report and review of the literature. Case Rep Oncol. 2021;14:232–8. CrossRef
28.
Zurück zum Zitat Mansfield AS, Wei Z, Mehra R, et al. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. Npj Precis Oncol. 2022;6:13. CrossRef Mansfield AS, Wei Z, Mehra R, et al. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. Npj Precis Oncol. 2022;6:13. CrossRef
29.
Zurück zum Zitat Mishra R, Patel H, Alanazi S, et al. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Med Sci. 2021;22:3464. CrossRef Mishra R, Patel H, Alanazi S, et al. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Med Sci. 2021;22:3464. CrossRef
30.
Zurück zum Zitat Grassi E, et al. Current therapeutic strategies in BRAF-mutant metastatic colorectal cancer. Front Oncol. 2021;11:601722. CrossRef Grassi E, et al. Current therapeutic strategies in BRAF-mutant metastatic colorectal cancer. Front Oncol. 2021;11:601722. CrossRef
Metadaten
Titel
Molecular profiling in colorectal cancer
verfasst von
Msc Gudrun Piringer
Publikationsdatum
29.08.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00833-6